Allogene Therapeutics (ALLO) Return on Sales (2021 - 2024)

Allogene Therapeutics has disclosed Return on Sales across 4 years of filings, most recently posting 115.1% for Q4 2024.

• Return on Sales for Q4 2024 came in at 115.1%, down 7756.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 115.1% (down 8253.0% YoY), and the FY2024 annual result was 117.09%, down 8264.0% from the prior year.
• Return on Sales came in at 115.1% for Q4 2024 at Allogene Therapeutics, down from 63.84% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2021 to a low of 115.1% in Q4 2024.
• The 4-year median for Return on Sales is 29.66% (2022), against an average of 31.87%.
• Across the five-year window, Return on Sales surged 437 bps in 2023 and plunged 7756 bps in 2024, its largest moves.
• Allogene Therapeutics' Return on Sales stood at 0.0% in 2021, then slumped by 14392819 bps to 36.01% in 2022, then slipped by 4 bps to 37.54% in 2023, then sank by 207 bps to 115.1% in 2024.
• The last three Return on Sales figures came in at 115.1% (Q4 2024), 63.84% (Q3 2024), and 40.95% (Q2 2024), per Business Quant data.